ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data.Virology journal · 2025Pooled it
- Discovery of 10-Shogaol fromJournal of agricultural and food chemistry · 2026Article
- Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database.Frontiers in pharmacology · 2026Article
- Severity of Primary and Secondary Dengue Virus 1 Infections: A Hospital-Based Study in Puerto Rico, 2012-2014.The American journal of tropical medicine and hygiene · 2025Article
- Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children.Diseases (Basel, Switzerland) · 2024Review
- Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.Journal of virology · 2023Article
- Current Understanding of the Role of T Cells in Chikungunya, Dengue and Zika Infections.Viruses · 2022Review
- Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors.Molecules (Basel, Switzerland) · 2021Article
- Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.Infectious diseases and therapy · 2020Article
- Designing effective control of dengue with combined interventions.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Rapid Induction and Maintenance of Virus-Specific CD8Frontiers in immunology · 2020Article
- Serostatus testing and dengue vaccine cost-benefit thresholds.Journal of the Royal Society, Interface · 2019Article
- Effects of infection history on dengue virus infection and pathogenicity.Nature communications · 2019Article
- Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody.eLife · 2018Article
- Reply to Aguiar and Stollenwerk.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- A dengue vaccine whirlwind update.Therapeutic advances in infectious diseaseReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Background: A recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) was licensed for children aged ≥9 years in a few countries, but the dependence of vaccine efficacy on baseline immunity status and age groups has not been fully characterized. Methods: Combining the 2 phase 3 trials CYD14 and CYD15, we estimated the vaccine efficacy for each of the 4 serotypes of dengue virus (DENV), as well as all serotypes combined, simultaneously stratified by baseline immunity status and age group, while accounting for uncertainty in the baseline immunity status of subjects. Results: Baseline seropositive subjects showed high efficacy for all serotypes: 70.2% (95% confidence interval [CI], 57.4%-80.1%) for dengue serotype 1 (DENV-1), 67.9% (95% CI, 49.9%-82.0%) for DENV-2, 77.5% (95% CI, 64.3%-90.2%) for DENV-3, 89.9% (95% CI, 79.8%-99.9%) for DENV-4, and 75.4% (95% CI, 68.3%-81.6%) overall. In contrast, baseline seronegative subjects showed moderate efficacy against DENV-4 (51.2% [95% CI, 20.0%-72.8%]) but no significant efficacy against other serotypes. Among seropositive children, the overall efficacy tended to increase with age: 35.9% (95% CI, -7.6% to 69.3%) for children ≤5 years old, 65.6% (95% CI, 40.3%-84.2%) for those 6-8 years old, 73.4% (95% CI, 62.6%-82.1%) for those 9-11 years old, and 80.6% (95% CI, 72.9%-87.3%) for those 12 years or older. Conclusions: The CYD-TDV vaccine was highly efficacious for all dengue serotypes among children aged >5 years who have acquired baseline immunity from previous exposure. Increasing vaccine efficacy with age was not fully explained by increasing prevalence of baseline immunity with age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.